Whitney Ijem

Canaccord Genuity | Healthcare

Whitney Ijem is an analyst from Canaccord Genuity specializing in the Healthcare sector. Ranked #154 out of 4525 analysts, they have issued 34 stock ratings with a success rate of 87.63% and an average return of 76.81%.

Whitney Ijem has a well-established track record, with 34 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 87.63% and an average return of 76.81%, underscoring their expertise and ability to identify winning opportunities for investors.

#154

Out of 4525

34

Total Ratings

+87.63%

Success Rate

+76.81%

Average Return

Recent Ratings Analysis

BMRN

Jan 20, 2026

Target

$98.00

Current

$56.31

Performance

0.00%

Whitney Ijem rated BMRN as Buy on Jan 20, 2026, setting a price target of 98. Shares have remained stable near 56.31, leaving the 98 target still in play.

TNYA

Dec 18, 2025

Target

$6.00

Current

$0.70

Performance

%

On Dec 18, 2025, TNYA was given a Buy rating by Whitney Ijem, with a target price of 6. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

PVLA

Dec 16, 2025

Target

$204.00

Current

$98.01

Performance

1.24%

PVLA received a Buy rating from Whitney Ijem on Dec 16, 2025, aiming for 204. Price action was muted, as shares hovered around 98.01 despite the bullish outlook.

RYTM

Dec 12, 2025

Target

$141.00

Current

$102.59

Performance

-9.64%

On Dec 12, 2025, Whitney Ijem published a Buy outlook on RYTM, with a target of 141. Market action contradicted the Buy thesis, as shares slipped to 102.59.

WVE

Dec 09, 2025

Target

$40.00

Current

$13.82

Performance

-35.15%

Whitney Ijem on Dec 09, 2025 assigned WVE a Buy rating, with a price target of 40. The call has struggled to gain traction, with shares losing 35.15%.

GUTS

Nov 21, 2025

Target

$8.00

Current

$1.91

Performance

36.43%

On Nov 21, 2025, Whitney Ijem reaffirmed GUTS with a Buy rating, targeting 8. The recommendation was supported by strong follow-through as the stock rose from 1.91 to 1.91.

GBIO

Aug 18, 2025

Target

$10.00

Current

$5.59

Performance

-15.69%

GBIO was rated Buy by Whitney Ijem on Aug 18, 2025, with a price objective of 10. This case shows how bullish projections can fail, with the stock now below 5.59.

PASG

Aug 14, 2025

Target

$67.00

Current

$12.77

Performance

68.25%

On Aug 14, 2025, Whitney Ijem initiated coverage on PASG with a Buy rating and target of 67. The stock’s climb of 68.25% since the call highlights the foresight in the rating.

TSHA

Aug 13, 2025

Target

$14.00

Current

$4.64

Performance

53.14%

Whitney Ijem issued a Buy recommendation for TSHA on Aug 13, 2025, price target set at 14. Investors following the Buy call captured upside momentum, with shares now at 4.64.

RARE

Aug 08, 2025

Target

$128.00

Current

$22.63

Performance

-17.83%

On Aug 08, 2025, RARE was evaluated by Whitney Ijem, who gave a Buy rating and target of 128. Investors saw limited payoff as shares fell short of the 128 target.

VRTX

Aug 06, 2025

Target

$411.00

Current

$442.08

Performance

14.63%

Whitney Ijem rated VRTX as Hold on Aug 06, 2025, setting a price target of 411. Despite the Hold call, shares climbed 14.63% to 442.08, revealing unexpected momentum.

ALNY

Aug 01, 2025

Target

$415.00

Current

$355.53

Performance

-11.52%

On Aug 01, 2025, ALNY was given a Buy rating by Whitney Ijem, with a target price of 415. Despite the Buy call, shares fell from 355.53 to 355.53, challenging the optimistic stance.

RCKT

Jul 25, 2025

Target

$10.00

Current

$3.64

Performance

15.92%

RCKT received a Buy rating from Whitney Ijem on Jul 25, 2025, aiming for 10. Momentum has favored the Buy call, with shares climbing from 3.64 to 3.64, rewarding those who trusted the recommendation.

VERV

Jun 17, 2025

Target

$13.00

Current

$11.13

Performance

-2.20%

On Jun 17, 2025, Whitney Ijem published a Hold outlook on VERV, with a target of 13. Sideways action left the Hold view intact, with no major move since 11.13.

RGLS

Mar 17, 2025

Target

$28.00

Current

$8.16

Performance

495.62%

Whitney Ijem on Mar 17, 2025 assigned RGLS a Buy rating, with a price target of 28. The Buy call aligned well with market performance, producing a gain of 495.62%.

ARCT

Mar 10, 2025

Target

$68.00

Current

$7.10

Performance

-50.31%

On Mar 10, 2025, Whitney Ijem reaffirmed ARCT with a Buy rating, targeting 68. Shares slid 50.31% despite the recommendation, highlighting downside risks.

NTLA

Nov 19, 2024

Target

$90.00

Current

$12.83

Performance

-9.20%

NTLA was rated Buy by Whitney Ijem on Nov 19, 2024, with a price objective of 90. This case shows how bullish projections can fail, with the stock now below 12.83.

Frequency Asked Questions

Who is Whitney Ijem?

Whitney Ijem is an analyst from Canaccord Genuity specializing in the Healthcare sector.

What is Whitney Ijem's success rate?

Whitney Ijem currently has a success rate of +87.63%.

How many ratings has Whitney Ijem issued?

Whitney Ijem has issued 34 stock ratings so far.

What is the average return of Whitney Ijem's calls?

Their stock ratings have generated an average return of +76.81%.

What is Whitney Ijem's ranking?

Whitney Ijem is ranked #154 out of 4525 analysts.

What types of ratings does Whitney Ijem give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Whitney Ijem?

You can follow Whitney Ijem by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Whitney Ijem?

Their latest rating was a Buy on BMRN issued on 2026-01-20.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep